Cork, Friday, 31 January 2025.GE HealthCare is investing $138 million in a new facility in Cork, Ireland to meet rising global demand for contrast media, aiming to provide 25 million more patient doses annually by 2027.
Strategic Expansion to Meet Growing Healthcare Demands
The investment announced on January 31, 2025, will see the construction of a state-of-the-art 3,000 m² facility at GE HealthCare’s Carrigtohill site in Cork [1][2]. This expansion comes at a critical time, as global demand for iodine-based contrast media, essential for CT scans and X-ray procedures, is projected to double within the next decade [1][3]. The company’s existing network, including facilities in Shanghai, China, and Oslo, Norway, supplied over 100 million patient doses globally in 2024 [1][4].
Advanced Manufacturing Capabilities
The new facility will incorporate cutting-edge technology, featuring solution preparation vessels, multifunctional powder handling systems, and a sophisticated filling line [1][3]. Construction is scheduled to begin in February 2025 [3], creating over 250 construction roles during the development phase [1]. The facility represents a significant advancement in GE HealthCare’s manufacturing capabilities, reinforcing their position as an industry leader in contrast media production [4].
Economic Impact and Local Investment
This expansion strengthens GE HealthCare’s three-decade presence in Ireland, where they have built a reputation for excellence in pharmaceutical manufacturing [4][5]. The investment has received strong support from local authorities, with Taoiseach Micheál Martin performing the groundbreaking ceremony [2]. Kevin O’Neill, President and CEO of GE HealthCare’s Pharmaceutical Diagnostics segment, emphasized that Cork was chosen for its ‘fantastic team’ and ‘great access to global markets’ [2].
Future Outlook and Global Healthcare Impact
The facility is expected to begin producing its first doses by the end of 2027 [1][4], addressing the increasing demand driven by aging populations and rising chronic disorders [1][3]. This investment is part of GE HealthCare’s broader strategy to enhance supply chain resilience and security in the contrast media industry [1]. The company, with its $19.6 billion business operations and approximately 51,000 employees globally, continues to demonstrate its commitment to advancing healthcare delivery worldwide [1].
